Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Repurchased
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGNDZ) Amortization of Deferred Charges (2016 - 2025)

Ligand Pharmaceuticals (LGNDZ) has disclosed Amortization of Deferred Charges for 14 consecutive years, with $565000.0 as the latest value for Q4 2025.

  • Quarterly Amortization of Deferred Charges rose 228.49% to $565000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.2 million through Dec 2025, up 152.26% year-over-year, with the annual reading at $1.3 million for FY2025, 161.93% up from the prior year.
  • Amortization of Deferred Charges hit $565000.0 in Q4 2025 for Ligand Pharmaceuticals, up from $400000.0 in the prior quarter.
  • In the past five years, Amortization of Deferred Charges ranged from a high of $4.9 million in Q1 2021 to a low of $81000.0 in Q4 2023.
  • Historically, Amortization of Deferred Charges has averaged $1.0 million across 5 years, with a median of $136000.0 in 2025.
  • Biggest five-year swings in Amortization of Deferred Charges: tumbled 97.52% in 2022 and later soared 228.49% in 2025.
  • Year by year, Amortization of Deferred Charges stood at $3.8 million in 2021, then crashed by 97.52% to $95000.0 in 2022, then dropped by 14.74% to $81000.0 in 2023, then skyrocketed by 112.35% to $172000.0 in 2024, then skyrocketed by 228.49% to $565000.0 in 2025.
  • Business Quant data shows Amortization of Deferred Charges for LGNDZ at $565000.0 in Q4 2025, $400000.0 in Q3 2025, and $125000.0 in Q2 2025.